Review: Correction provides value opportunity
The Biotech Growth Trust (BIOG) aims to achieve growth by investing in biotechnology companies around the world, though in practice it is heavily weighted to North America (86%). A recent change to its investment mandate has allowed it to invest more in larger companies, reflecting both the growth in the sector and the managers’ view that many major biotech firms have a more attractive growth and valuation profile than earlier-stage companies, although it continues to have a significant weighting (c 34% of the portfolio) in emerging biotech. A sharp correction in biotech stocks since March may present an attractive entry point for investors, with BIOG shares moving to a discount after trading at a premium for much of 2013.Biotech Growth Trust is an investment trust company. Co. invests in a range portfolio of shares and related securities in biotechnology companies on a worldwide basis. Co.'s alternative investment fund manager is Frostrow Capital LLP and its portfolio manager is OrbiMed Capital LLC. As of Mar 31 2017, Co. had total investment of £461.4 million.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.